glp-1 drugs in development Medications for Weight Loss: Semaglutide vs Tirzepatide vs Retat – Revolution Health & Wellness Science's 2023 Breakthrough: GLP-1R Agonists

At 6 months, the incidence in the GLP-1 RA group was 9.36%, compared to 4.76% in the non-GLP-1 RA group

Note: The studies presented in this table describe direct effects of GLP-1 RAs, on macro- and microvascular coronary arteries

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus

It is FDA-approved for Type 2 diabetes but is sometimes prescribed off-label for weight loss

Cells producing and secreting enteroglucagon were originally identified by immunohistochemistry with glucagon antibodies and it was noted that the cells in the gut mucosa differed from islet -cells that produce glucagon (42)

Such strategies should be based on reinforcing persistence and adherence to the prescribed treatment and reducing therapeutic inertia